Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Madrigal Pharmaceuticals (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.…
497,210$
-3,63%
Echtzeit-Aktienkurs Madrigal Pharmaceuticals Corp.
Bid:
Ask:
Nachrichten zur Madrigal Pharmaceuticals Corp. Aktie
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
The FDAs decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are…
Madrigal Pharmaceuticals: Hammer-Nachricht! Aktienanalyse
Kulmbach (www.aktiencheck.de) - Madrigal Pharmaceuticals-Aktienanalyse von "Der Aktionär":
Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Madrigal…
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering…
AKTIONÄR-Hot-Stock Madrigal: Die Entscheidung des Jahres
Im Biotech-Sektor sollten Anleger in dieser Handelswoche vor allem die Aktie von Madrigal Pharmaceuticals im Auge behalten. Denn das Unternehmen…
AKTIONÄR-Hot-Stock Madrigal: Die Entscheidung des Jahres
Im Biotech-Sektor sollten Anleger in dieser Handelswoche vor allem die Aktie von Madrigal Pharmaceuticals im Auge behalten. Denn das Unternehmen…
Madrigal Pharmaceuticals names new CFO amid growth phase By Investing.com
Madrigal Pharmaceuticals names new CFO amid growth phase…
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel…